News and Events

Seldom-studied immune cells in the liver may be helpful in treating cancer

CCR researchers have discovered that certain immune cells in the liver, called MAITs, often surround liver tumors but fail to infiltrate them. An analysis suggests that treatment with immune checkpoint inhibitors could potentially trigger these immune cells to help them infiltrate and attack the tumors.

Clinical trial researches bone marrow transplants for blood cancers

A clinical trial led by Christopher G. Kanakry, M.D., Lasker Clinical Research Scholar in the Center for Immuno-Oncology, is researching bone marrow transplants for some types of blood cancers, such as high-risk leukemia, lymphoma, myelodysplastic syndrome or multiple myeloma.

CCR Hosts Communications Course for Healthcare Providers in Oncology

Dedicated transdisciplinary teams of healthcare providers from the CCR’s Clinical Care Programs gathered to learn communication skills centered on essential topics of patient care.

A stain of HPV-negative head and neck squamous cell carcinoma that has high levels of SMYD3

Chromatin modifier linked to immunotherapy resistance in HPV-negative head and neck cancers

Researchers have discovered that a chromatin-regulating enzyme called SMYD3 limits the access of cancer-attacking immune cells to HPV-negative head and neck cancers, therefore decreasing immunotherapy’s effectiveness. Depleting SMYD3 increased the cancer’s sensitivity to a standard immunotherapy drug in mouse models.

New insights explain how the same protein can serve different functions

Proteins can often choose between potential interacting partners and serve different functions inside cells. How these choices are made is not entirely clear. New research shows that the exact location in a cell where the protein is produced and the rate of its synthesis are key factors in this choice.

New T-cell therapy shrinks solid tumors in early-phase clinical trial

Trial results show that engineered T cells can effectively target mesothelin, a protein found on many solid tumors.

Studies of an experimental ovarian cancer therapy identify a biomarker of treatment response

A new biomarker may identify patients who can benefit from drugs that inhibit CHK1 after their ovarian cancer has become resistant to PARP inhibitors.

Remembering Miranda Leah Hanson-Baseler, an indomitable immunologist

Faced with a uterine sarcoma diagnosis at just 24, Miranda Leah Hanson-Baseler persevered through treatments for 17 years.

New analysis reveals potential effective drug combinations for treating lung cancer

Researchers compared more than 5,000 drug combinations in lung cancer cells, the results of which point to combinations that may be particularly effective in combating cancer in humans.

Aligned Blog: Mentoring Across Difference

For many people, navigating higher education and entering the workforce can be challenging but having a good mentor, especially one who considers how your background impacts your lived experience, can make a difference. In this blog, the Office of Equity and Inclusion's newest team member, Sonia A. Garcia, Ph.D., writes about her experience navigating through a Ph.D. program as a first-generation Latina student and the importance of mentoring across difference.

Breadcrumb